Ishape 60mg Capsule contains Orlistat, a potent lipase inhibitor indicated for the management of obesity. Orlistat acts locally in the gastrointestinal tract by selectively inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By preventing the breakdown and subsequent absorption of approximately 30% of dietary fat, Ishape facilitates weight loss and aids in the maintenance of reduced body weight when used in conjunction with a reduced-calorie diet and exercise. It is primarily prescribed for adults with a body mass index (BMI) ≥30 kg/m², or ≥27 kg/m² in the presence of obesity-related risk factors such as hypertension, type 2 diabetes mellitus, or dyslipidemia. The recommended dosage is one 60mg capsule taken orally three times daily with each main meal containing fat. Common adverse effects include gastrointestinal symptoms such as oily spotting, flatulence with discharge, and fecal urgency, which are generally mild and related to fat malabsorption. Patients should adhere to a nutritionally balanced, reduced-fat diet to minimize side effects and ensure adequate intake of fat-soluble vitamins. Ishape is contraindicated in patients with chronic malabsorption syndrome or cholestasis and should be used cautiously in individuals on concomitant anticoagulant therapy. Regular monitoring and patient counseling are essential to optimize therapeutic outcomes.